Discovery of circulating blood biomarkers in patients with and without Modic changes of the lumbar spine: a preliminary analysis
Purpose The following study aimed to determine the existence of blood biomarkers in symptomatic patients with or without lumbar Modic changes (MC). Methods A cross-sectional sub-analyses of a prospective cohort was performed. Fasting blood samples were collected from patients with and without lumbar...
Saved in:
Published in | European spine journal Vol. 33; no. 4; pp. 1398 - 1406 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.04.2024
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Purpose
The following study aimed to determine the existence of blood biomarkers in symptomatic patients with or without lumbar Modic changes (MC).
Methods
A cross-sectional sub-analyses of a prospective cohort was performed. Fasting blood samples were collected from patients with and without lumbar MC who had undergone spinal fusion or microdiscectomy. An 80-plex panel and CCL5/RANTES were used to assess preoperative plasma cytokine concentrations. Patient demographics and imaging phenotypes were also assessed.
Results
Thirty-one subjects were analysed (
n
= 18 no MC;
n
= 13 MC). No significant differences were found in age, sex, body mass index, smoking and alcohol history, and surgical procedure (i.e. fusion, decompression) between the two groups (
p
> 0.05). Several statistically significant blood biomarkers in MC patients were identified, including elevated levels of C–C Motif Chemokine Ligand 5 (CCL5,
p
= 0.0006), while Macrophage Migration Inhibitory Factor (MIF) was significantly lower (
p
= 0.009). Additionally, C-X-C Motif Chemokine Ligand 5 (CXCL5,
p
= 0.052), Pentraxin 3 (PTX3,
p
= 0.06) and Galectin-3 (Gal-3,
p
= 0.07) showed potential relevance. Moreover, MC patients exhibited significantly higher levels of disc degeneration (
p
= 0.0001) and displacement severity (
p
= 0.020). Based on multivariate analyses and controlling for disc degeneration/displacement, CCL5 (OR 1.02; 95% CI 1.002–1.033;
p
= 0.028) and MIF (OR 0.60; 95% CI 0.382–0.951;
p
= 0.030) were independently associated with MC patients.
Conclusion
This “proof-of-concept” study is the first to identify specific and significantly circulating blood biomarkers associated with symptomatic patients with lumbar MC, independent of disc alterations of degeneration and/or bulges/herniations. Specifically, differences in CCL5 and MIF protein levels were significantly noted in MC patients compared to those without MC. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 0940-6719 1432-0932 1432-0932 |
DOI: | 10.1007/s00586-024-08192-y |